Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Director dealings

Cyprotex PLC ("Cyprotex" or the "Company")

Macclesfield, UK - Cyprotex PLC (LSE: CRX), a Contract Research Organisation (CRO) specialising in the preclinical ADME assessment of drug candidates, was informed on 17 August 2010 that certain directors acquired ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 17 August 2010. Details of the dealings are set out below:

Name

Title

 Price 

Shares acquired

Total interest

following dealing

% of total issued share capital

Steve Harris

Chairman

3.50

714,286

1,514,286

0.68

Anthony Baxter

CEO

3.50

228,571

1,069,971

0.48

John Dootson

CFO

3.50

550,000

550,000

0.25

Katya Tsaioun

CSO

3.50

1,828,571

24,193,720

10.82

Douglas Bates

CMO

3.50

5,485,715

27,850,862

12.45

 

For further information please contact:

Cyprotex PLC

Tel: +44 1625 505 10

Dr. Anthony Baxter, Chief Executive Officer

 

a.baxter@cyprotex.com

 

www.cyprotex.com

 

   

Singer Capital Markets Ltd

Tel: +44 203 205 7500

Shaun Dobson

 

Claes Spång

 

   

Financial Dynamics

Tel: +44 207 831 3113

Ben Brewerton

 

Ben Atwell

 

Mo Noonan

 

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close